Adamis Pharmaceuticals Omakapital 2024

Mis teeb Adamis Pharmaceuticals?

Adamis Pharmaceuticals Corp is a biotechnology company based in the USA that specializes in the development of pharmaceuticals and medical devices. The company was founded in 2006 and is headquartered in San Diego, California. History: Adamis Pharmaceuticals was founded by Dr. Dennis J. Carlo, an experienced pharmaceutical executive with over 35 years of industry experience. The company initially focused on the development of therapeutics for the treatment of allergies and respiratory diseases. Over the years, the company has expanded its portfolio and specialized in the development of drugs for the treatment of anaphylaxis, asthma, and prostate cancer, as well as medical devices for drug delivery. Business model: Adamis Pharmaceuticals focuses on the development of novel drugs and medical devices that can improve patients' lives. The company seeks opportunities to meet unmet medical needs in existing therapy areas. Adamis collaborates closely with leading medical institutions and research facilities to develop and market a portfolio of innovative products. Various divisions: The company has various divisions, including: 1. Allergy/Respiratory: Adamis Pharmaceuticals has developed a broad portfolio of therapeutic agents for the treatment of allergies and respiratory diseases. The company has also developed a patented device called Symjepi, which is used to treat anaphylaxis, a life-threatening allergic reaction. This device also allows untrained individuals to self-treat in an anaphylaxis situation. 2. Oncology: Adamis Pharmaceuticals has developed a novel drug called TeloBlast®, which is used to treat prostate cancer. TeloBlast® targets telomerase, which is upregulated in many types of cancer. The company intends to develop additional drugs for the treatment of cancer in the future. 3. CNS: Adamis Pharmaceuticals has also developed innovative drugs for the treatment of CNS (central nervous system) disorders. The company plans to bring several new drugs for the treatment of neurological disorders to the market by 2022. 4. Medical devices: Adamis Pharmaceuticals has developed a range of patented medical devices, including the ZIM high-pressure injection pump, which allows doctors and nurses to administer medications quickly and accurately. Products: Adamis Pharmaceuticals' products include: 1. Symjepi: A patented device for the treatment of anaphylaxis. 2. TeloBlast®: A novel drug for the treatment of prostate cancer. 3. ZIM high-pressure injection pump: A patented medical device for drug administration. 4. Fluticasone/Salmeterol: An inhalable combination drug for the treatment of asthma and COPD (chronic obstructive pulmonary disease). Adamis Pharmaceuticals is an innovative biotechnology company specializing in the development of pharmaceuticals and medical devices. The company aims to meet unmet medical needs and improve patients' lives. With a broad portfolio of products and a strong commitment to research and development, Adamis Pharmaceuticals is well positioned to continue growing in the future. Adamis Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.